


## **In Healthy People a Widespread Hydrogenase Supports Fermentative Growth of Gut Bacteria**

An international team of researchers leveraged a multifaceted study combining [genomic](#), transcriptomic, and biochemical analyses to identify the primary driver of fermentative molecular hydrogen (H<sub>2</sub>) production in healthy individuals. Molecular H<sub>2</sub> cycling is a vital metabolic process in the human gut, but the specific microbes and enzymes responsible for it remain unresolved.



### **Study**

The present study aims to address this knowledge gap and inform future research and gastrointestinal interventions by leveraging a multi-pronged approach to elucidate the microbes and enzymes involved in H<sub>2</sub> production from the ecosystem level down to the single [enzyme](#).

The study comprised several sequential steps: First, a large-scale computational analysis of 300 stool metagenomes and 78 [metatranscriptomes](#) was carried out to elucidate the full spectrum of hydrogen-related genes present and active in the healthy human gut. These findings were validated using 102 mucosal biopsy-enriched metagenomes from 42 donors. Furthermore, analyses focused on samples from the terminal ileum, caecum, and rectum to confirm consistency across gut regions.

Next, to demonstrate that these genes were functional, the study selected 19 diverse bacterial species from the human gut and grew them under anaerobic (oxygen-free) conditions to simulate gut conditions. [Gas chromatography](#) assays were used to precisely measure the amount of H<sub>2</sub> gas produced by each bacterial isolate over time.

Finally, biochemical assays (on bacterial cell extracts) were carried out to elucidate the link between H<sub>2</sub> production and pyruvate:ferredoxin oxidoreductase (PFOR) reaction, a core part of fermentation. Specifically, PFOR substrates (pyruvate and CoA) and inhibitors were added to see how H<sub>2</sub> levels responded, supported by AlphaFold2 modelling, [heterologous expression](#), and spectroscopy/EPR evidence that validated the enzyme's ferredoxin-like domain and catalytic function.

### **Results**

Study findings revealed, for the first time, that the group B [FeFe]-hydrogenase enzyme was, by far, the most dominant hydrogen-producing gene in the healthy [human gut](#). Abundance estimates found that group B genes were on average  $0.75 \pm 0.25$  copies per genome, about 7.5 times more abundant than the group A1 enzyme ( $0.10 \pm 0.09$  copies), which was previously thought to be the leading H<sub>2</sub> producer.

Activity assays supported these findings, showing that group B [genes](#) were also the most highly transcribed (active) in the metatranscriptome. Unexpectedly, however, activity assays revealed *Bacteroides*, one of the most common genera in the gut, as a primary user of group B enzymes and thus a major H<sub>2</sub> producer, a previously under-recognized association.

Analyses of the 19 bacterial isolates confirmed these findings, demonstrating that species encoding the group B gene, including seven different *Bacteroides* isolates, produced high levels of H<sub>2</sub> gas. In contrast, *Bacteroides stercoris*, a species that naturally lacks any hydrogenase genes, was observed to produce no H<sub>2</sub>, consistent with the absence of detectable hydrogenase genes.

Most significantly, comparing healthy individuals to 46 patients with CD revealed that the “healthy” group B hydrogenase was significantly depleted ( $P = 0.0023$ ) and notably replaced by other enzymes: the group A1 hydrogenase increased 2.8-fold ( $P = 6.6 \times 10^{-7}$ ), the group 4a formate hydrogenlyase (often found in *E. coli*) increased 5.2-fold ( $P = 6.8 \times 10^{-6}$ ), and the group 1d [NiFe]-hydrogenase increased 2.6-fold ( $P = 3.8 \times 10^{-5}$ ). Genes for respiratory [H<sub>2</sub> oxidation](#), particularly group 1d [NiFe]-hydrogenases, also increased, supporting a restructured hydrogen economy in the inflamed gut of CD patients.

Expression also varied markedly between individuals, and the combined [FeFe] subgroups were not significantly different between CD and control samples, underscoring that these associations are correlative and require further mechanistic study. Respiratory hydrogenotrophs likely dominate gut H<sub>2</sub> consumption, based on gene abundance and [transcription data](#), though activity-level validation is still needed.

## **Conclusion**

The present study refines and consolidates scientific understanding of a fundamental [metabolic process](#) in the human gut, identifying the group B [FeFe]-hydrogenase as the primary driver of fermentative H<sub>2</sub> production in healthy individuals and elevating the *Bacteroides* genus to a key player.

This discovery opens new avenues for understanding, diagnosing, and potentially treating complex inflammatory gut [disorders](#) by leveraging interventions targeting the gut microbiome. It also suggests that respiratory hydrogenotrophs are major consumers of H<sub>2</sub>, underscoring the complexity of microbial energy flow in the gut ecosystem.

## **Source:**

<https://www.news-medical.net/news/20251027/Scientists-uncover-the-gute28099s-hidden-hydrogen-engine-and-how-it-falters-in-Crohne28099s-disease.aspx>